Article Text
Statistics from Altmetric.com
Sodium–glucose cotransporter-2 (SGLT-2) inhibitors are effective antihyperglycemic agents with proven cardiovascular and renal benefits.1 2 The risk for acute kidney injury (AKI) in patients on SGLT-2 inhibitors is considered to be relatively low. However, there have been postmarketing reports of episodes of AKI, some requiring hospitalisation and even dialysis in patients receiving SGLT-2 inhibitors.3 This phenomenon may be related to volume contraction and haemodynamic changes, particularly in patients with other risk factors (such as patients on renin–angiotensin–aldosterone system blocking agents or non-steroidal anti-inflammatory drugs, patients with chronic kidney disease).4 Here, we present a case of acute interstitial nephritis (AIN) and acute tubular necrosis likely related to a SGLT-2 inhibitor.
A 67-year-old woman was admitted with weakness, dizziness and abdominal pain. Her medical history was remarkable for hypertension, diabetes mellitus, ischaemic heart disease and peripheral vascular disease. Her medications …
Footnotes
Contributors AB drafted the manuscript. LS, EI, JA and MA-A contributed to the critical revision of the manuscript and final approval of the manuscript.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.